

**Espacenet****Bibliographic data: SI1863526 (T1) — 2011-11-30**

LIVE ATTENUATED ROTAVIRUS VACCINE FOR ORAL ADMINISTRATION

Inventor(s): VANDE VELDE VINCENT [BE] ± (VANDE VELDE VINCENT)

Applicant(s): GLAXOSMITHKLINE BIOLOG SA [BE] ± (GLAXOSMITHKLINE BIOLOGICALS S.A)

Classification: - international: **A61K39/15; A61P1/00**
- cooperative: A61K39/15; A61K2039/5254; A61K2039/542;
A61K2039/545

Application number: SI20060031128T 20060215

Priority number (s): GB20050003337 20050217 ; WO2006EP01442 20060215 ; EP20060707035 20060215

Also published as: WO2006087205 (A1) ZA200706668 (A) UY29377 (A1)
US2012237547 (A1) US2008166372 (A1) more

Abstract not available for SI1863526 (T1)**Abstract of corresponding document: WO2006087205 (A1)**

The invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. The invention also provides methods of preparing said rotavirus formulations and use thereof in the prevention or treatment of rotavirus associated diseases in humans.